The results of our study do not justify the omission of a necessary transfusion; however, our findings might implicate a more restrictive transfusion management in patients undergoing IT and encourage the use of alternatives, such as erythropoietin to treat tumor-induced or treatment-associated anemia, if feasible. This evidence concerns the gene EPO and anemia (phenotype).